Señales en vivo de MDGL | Maximiza tus Ganancias con Getagraph.com

COMPRAR 1412 min ago

@ $230.59

Emitido: 3 may 2024 @ 15:13

Retorno: -0.33%

Señal anterior: may 3 - 09:30

Señal anterior: Vender

Retorno: 3.24 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	433 785
Volumen promedio	612 738
Capitalización de mercado	4.83B
EPS	$-5.68 ( 2024-02-29 )
Próxima fecha de ganancias	( $-6.06 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.50
ATR14	$12.98 (5.67%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Taub Rebecca	Buy	2 676	Common Stock
2024-04-08	Taub Rebecca	Sell	224	Common Stock
2024-04-08	Taub Rebecca	Sell	945	Common Stock
2024-04-08	Taub Rebecca	Sell	300	Common Stock
2024-04-08	Taub Rebecca	Sell	600	Common Stock

INSIDER POWER
-31.13
Last 100 transactions
Buy: 220 053 \| Sell: 418 887

Volumen Correlación

Largo: -0.74 (moderate negative)

Corto: 0.11 (neutral)

Signal:(48) Neutral

Madrigal Pharmaceuticals Correlación

10 Correlaciones Más Positivas
GOSS	0.82

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Madrigal Pharmaceuticals Correlación - Moneda/Commodity

0.04
( neutral )

-0.61
( weak negative )

-0.15
( neutral )

0.13
( neutral )

0.26
( neutral )

0.83
( strong )

Madrigal Pharmaceuticals Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-527 000 (0.00 %)
EPS:	$-19.99

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-527 000 (0.00 %)
EPS:	$-19.99

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-467 000 (0.00 %)
EPS:	$-17.47

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-14.63

Financial Reports:

No articles found.

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Actualizaciones en tiempo real para Madrigal Pharmaceuticals [MDGL]

Upcoming Earnings Alert